Advances in the treatment of metastatic melanoma have improved responses and survival.
However, many patients continue to experience resistance or toxicity to treatment, …

The development of BRAF and MEK inhibitors (BRAFis and MEKis) and immune checkpoint
inhibitors have changed the management of advanced stage melanoma and improved the …

Background Immune checkpoint therapy has dramatically changed the landscape of cancer
therapy, providing an efficacious and durable therapeutic option for patients with advanced-…

Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer,
but the effect of diet and supplements on this interaction is not well studied. We assessed …

… and other cancers the potential for long-term survival, and we are beginning to gain
insight into the mechanisms of therapeutic responses as well as biomarkers of response and …

Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and
PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-…

Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …

Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is
associated with enhanced survival and antigen-specific T cell responses compared with …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma 1 . We …